Progyny (PGNY) drew fresh investor attention after a research upgrade from Canaccord Genuity, which cited six consecutive quarters of revenue and adjusted EBITDA beats and highlighted expectations for a return to double digit revenue growth in late 2026.

Progyny's recent upgrade comes after a 36.93% 1 month share price return and a 19.73% 3 month share price return. However, the year to date share price return is still down 3.34% and the 3 year total shareholder return has declined 33.46%, suggesting short term momentum is improving against a weaker longer term record.

If the Progyny move has caught your eye, this could be a good moment to compare it with other healthcare focused AI opportunities via our 34 healthcare AI stocks.

With Progyny trading at a discount to analyst targets and a sizable gap to some intrinsic value estimates, the key question is simple: are you looking at an undervalued fertility benefits specialist, or has the recent rally already priced in the next leg of growth?

Most Popular Narrative: 19.5% Undervalued

Progyny's most followed narrative pegs fair value at $30.91, well above the last close at $24.88. This creates a valuation gap investors may want to understand.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Curious what kind of revenue growth, margins, and future P/E multiple have to line up to explain that fair value gap and the current discount rate? The full narrative walks through a detailed earnings trajectory, share count assumptions, and the profitability profile that underpin this 6.98% discount rate driven model.

Result: Fair Value of $30.91 (UNDERVALUED)

However, risks around employer cost cutting and potential regulatory changes to reproductive health benefits could still disrupt the earnings path that underpins the 19.5% undervaluation story.

Another View: Earnings Multiple Keeps Things Tighter

Our DCF model points to a fair value of $62.43, which implies a very large gap to the $24.88 share price. Yet on a simple P/E comparison, Progyny trades at 28.8x versus a 24.6x sector average and a fair ratio of 28.3x, which looks much closer. So is the opportunity as wide as the DCF suggests, or is the market already pricing in a lot of the story?

Next Steps

Given the mixed signals on valuation and sentiment, it makes sense to review the full data set yourself and decide how compelling Progyny really is. To understand what is driving the current optimism, take a closer look at the 3 key rewards.

Ready For More Investment Ideas?

If Progyny has sharpened your focus, do not stop here. Cast a wider net across other stocks so you do not miss opportunities that fit your style.

• Target potential mispriced opportunities by scanning companies that look cheaper than their fundamentals might suggest using the 48 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks offering higher yields and payout strength through the 10 dividend fortresses.
• Prioritize resilience by checking out companies with robust finances and quality metrics via the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.